The investigation also ensures Dorzolamide Trusopt mechanical. HSD17B2 is one of the enzymes downstream Rts in the axis of androgens in the conversion of DHEA stero And downstream Rts of DHT to androstanediol. Currently, new inhibitors of target HSD17B2 be developed. It is speculated appear that perhaps the loss of allelic HSD17B2 loci containing tumor cells of the prostate Kr Fte alternative routes such as DHT synthesis backdoor treatment, resistance to use. In future studies on genetic Ver Changes in loci to investigate the genes HSD17B2 this potential mechanism of resistance can be better understood. The expected results of this work is in the prediction of response to treatment of new inhibitors currently being prepared and tested important. CYP17A1 and SRD5A1 / 2 are enzymes of androgen that targeted agents currently used in therapy for prostate cancer. The abiraterone acetate, ketoconazole, finasteride, dutasteride and inhibitors, which were presented to demonstrate the clinical effectiveness in prostate cancer. In this cohort, it seems that genetic changes Ver Of loci contain CYP17A1, SRD5A1 and SRD5A2 low frequency and are therefore as a DNA-based biomarkers unlikely that pr Are predictive of a biochemical reaction to radiation and these new agents. Future studies on monoallelic loss of these loci decreased the expression / function for more conclusive data about a poor prognosis ben Be taken. In the medium to high risk of developing clinical studies have shown that combined radiotherapy and ADT survive most advantageous in terms of disease-specific, local progression, distant metastases, biochemical failure, and overall survival than radiotherapy alone. Combined with radiation therapy as novel agents for the F Promotion of androgen axis begin clinical trials in patients with intermedi Rem disease risk is evaluated, it will be interesting to evaluate the r Of the star, HSD17B2, and other genes in androgen synthesis post-radiotherapy biochemical relapse. This can be combined with important implications for determining the optimal timing of modality Th with radiotherapy and optimal agents for use in such combinations. There are a number of Restrict Website will this study. First, these results are based on DNA, there are other prognostic factors, in line with androgen RNA expression and tissue microarray-based immunohistochemical methods, which are connected with k One Nnte change in radiation therapy. To our knowledge, there is no such study for prostate cancer, but in a clinical study Elaziz Abd et al. Loss of mRNA expression with a poor prognosis in other cancers of the endocrine system Star went born. Future studies that these genes into DNA, RNA, Ren married And Eiwei content As factors influencing the biochemical reaction in radiotherapy of prostate cancer after radiation therapy or more ADT to determine treatment are justified. Second, our results suggest that changes Ver In the regions, the axitinib star and HSD17B2 genes are predictive of biochemical failure. Although these regions are relatively small, k can Other genes they contain and therefore we may use the not definitely say that STAR and HSD17B2 are the biological engines of this observation to a poor prognosis. This hypothesis.